Verheugt F
Department of Cardiology, University Hospital Nijmegen, The Netherlands
Rev Port Cardiol. 1998 Dec;17(12):959-65.
The optimal thrombolytic regimen is front-loaded alteplase with vigorous heparinization: the reperfusion treatment that leads to the lowest 30 day mortality. The role of heparin alone or in combination with thrombolysis is still unclear. Hirudin does not provide benefit over heparin, as we have seen in the trials, and glycoprotein blockers are promising in PTCA. They can also be effective in unstable angina and possibly in acute myocardial infarction.
这种再灌注治疗可使30天死亡率降至最低。单独使用肝素或与溶栓联合使用的作用仍不明确。正如我们在试验中所见，水蛭素并不比肝素更具优势，而糖蛋白阻滞剂在经皮冠状动脉腔内血管成形术（PTCA）中很有前景。它们在不稳定型心绞痛中也可能有效，或许对急性心肌梗死也有效。
